TR563 for osteoporosis

The market for osteoporosis is near 9 billion US dollars and believed to increase year by year. Bisphosphonates are small molecule drugs and used to treat osteophorosis for decades. Their market shares are close to 3 billion US dollars meaning bisphosphonates are the major treatments for osteoporosis. However, bisphosphonates including oral form and injection often cause serious side effects like esophageal cancer, jaw osteonecrosis and femoral fracture. To avoid those side effects, the development of transdermal dosage is a solution. Our product, TR563, is a topical gel containing alendronate as active ingredient. In vivo studies show TR563 increases the bone density of ovariectomized rats and penetrate rabbit skin with sustained release profile and low skin irritation.